Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some statements match the provided label excerpts (mechanism, indication for LDL-C lowering, dosing frequency, statin combination, liver enzyme monitoring language, and myopathy/rhabdomyolysis). However, several safety statements (diabetes risk, kidney damage, specific hepatitis/pancreatitis claims, and absolute renal/hepatic/muscle contraindications) are not supported or are contradicted by the supplied label text, and the 18–20% LDL-C reduction claim is not supported by the provided sections.
Category Scores
Accurate Statements
Ezetimibe inhibits the absorption of cholesterol in the small intestine.
Label 12.1: “Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine.”
Ezetimibe is prescribed in combination with statins.
Label 1: “In combination with a statin…” and additional combination indications.
Ezetimibe is typically taken once a day.
Label 2: “The recommended dose of ZETIA is 10 mg orally once daily…”
Ezetimibe is effective in lowering LDL (bad) cholesterol levels.
Label 12.2/14: “ZETIA reduces… LDL-C” and “ZETIA significantly lowered… LDL-C…”
Ezetimibe can cause muscle pain.
Label 5.3: “ZETIA may cause myopathy [muscle pain, tenderness, or weakness associated with elevated creatine kinase (CK)]…”
Ezetimibe can cause rhabdomyolysis.
Label 5.3: “…myopathy… and rhabdomyolysis…”. Also 6: “Rhabdomyolysis and myopathy…”.
Patients taking ezetimibe should have regular liver function tests to monitor for changes.
Label 5.2: “Perform liver enzyme testing as clinically indicated…” (supports liver testing; “regular” is not explicitly stated).
Ezetimibe can cause allergic reactions.
Label 4: “Hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria…”
Unsupported Statements
Ezetimibe reduces LDL cholesterol levels by an average of 18-20% in clinical trials (per manufacturer).
Provided label excerpts show LDL-C percentage changes in tables (e.g., -18% in one monotherapy table; other pooled values vary), but no statement in the supplied text supports a general “average of 18–20%” claim across trials.
Ezetimibe can cause liver damage.
Label excerpt discusses liver enzyme abnormalities and testing/possible withdrawal; it does not state “liver damage” as a specific adverse outcome.
Ezetimibe can increase the risk of developing diabetes.
No diabetes risk/diabetes warnings are present in the provided label sections.
Patients taking ezetimibe should be monitored for signs of diabetes such as increased thirst and urination.
No diabetes monitoring language is present in the provided label sections.
Ezetimibe can cause kidney damage.
No kidney-damage claim is present in the provided label excerpts.
Patients taking ezetimibe should have regular kidney function tests to monitor for changes.
No kidney function monitoring guidance is present in the provided label excerpts.
Ezetimibe can cause hepatitis.
The provided excerpt does not mention hepatitis.
Ezetimibe can cause pancreatitis.
The provided excerpt does not mention pancreatitis.
Patients with kidney disease should not take ezetimibe.
Provided label excerpt 8.6 states: “No dosage adjustment of ZETIA is necessary in patients with renal impairment.” This does not support an instruction not to take it.
Patients with muscle disease should not take ezetimibe.
Provided label excerpt does not list a contraindication or instruction related to pre-existing muscle disease.
Contradictions
Low
AI Statement
Ezetimibe is not recommended for use during pregnancy.
Label Reference
Label 8.1: “ZETIA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.” (This is not the same as “not recommended for use.”)
Low
AI Statement
Ezetimibe is not recommended for use during breastfeeding.
Label Reference
Label 8.2: “ZETIA should not be used in nursing mothers unless the potential benefit justifies the potential risk to the infant.” (This is conditional, not an absolute “not recommended.”)
Low
AI Statement
Patients with liver disease should not take ezetimibe.
Label Reference
Label 8.7: “ZETIA is not recommended for use in patients with moderate to severe hepatic impairment (Child-Pugh B or C)…” This is narrower than “liver disease” broadly.
Important Omissions
Missed-dose instruction (do not double next dose) and possible timing separation from bile acid sequestrants (at least 2 hours before or 4 hours after).
Importance:
Moderate
The label’s indication for ezetimibe monotherapy/adjunct “as an adjunct to diet” and pediatric ages for specific indications (not evaluated in the provided claims).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some statements suggest monitoring/risks (diabetes risk, kidney damage, hepatitis, pancreatitis, absolute renal/muscle/liver avoidance) that are not supported by the provided label excerpts, and pregnancy/lactation statements are phrased as absolute “not recommended” rather than conditional benefit-risk language. These could lead to inaccurate counseling or inappropriate focus. One statement about liver testing is partially supported (though “regular” is not explicitly stated).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Several safety and contraindication-related claims (diabetes risk, kidney damage/monitoring, hepatitis/pancreatitis, and absolute avoidance in kidney/muscle disease) are not supported by the supplied label excerpts; pregnancy/breastfeeding phrasing is more absolute than the label’s conditional instructions.
Suggested Improvement
Align safety and population statements strictly to the supplied label text (e.g., replace diabetes/renal/kidney-damage and hepatitis/pancreatitis claims with supported warnings such as liver enzyme abnormalities and myopathy/rhabdomyolysis). Use the label’s conditional pregnancy/lactation language (“only if the potential benefit justifies the potential risk” / “should not be used… unless benefit justifies risk”) and narrow hepatic impairment language to moderate-to-severe Child-Pugh B/C when referencing 8.7. Avoid asserting “regular” monitoring unless explicitly stated.